Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Lung Cancer|Solid Tumor|Gastric Cancer|Urothelial Cancer|Endometrial Cancer|Multiple Myeloma|Myeloproliferative Neoplasms|Breast Cancer|Cholangiocarcinoma|UC|MPN
Interventions: DRUG: Pemigatinib|DRUG: Gemcitabine|DRUG: Pembrolizumab|DRUG: Docetaxel|DRUG: Trastuzumab|DRUG: Retifanlimab|DRUG: Cisplatin
Sponsor: Incyte Corporation